We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) has received a complete response letter on its Avodart sNDA for reducing the risk of prostate cancer in men at increased risk for the disease.